东方生物：2025年净利润亏损5.64亿元

Core Viewpoint - The company reported a total operating revenue of 959 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 15.83%. However, the net profit attributable to the parent company was a loss of 564 million yuan, a decrease of 6.54% compared to the previous year [1]. Group 1: Financial Performance - The total operating revenue for 2025 reached 959 million yuan, marking a growth of 15.83% from the previous year [1]. - The net profit attributable to the parent company was a loss of 564 million yuan, which represents a decline of 6.54% year-on-year [1]. Group 2: Business Operations - The company's main business maintained steady development during the year [1]. - Significant investments were made in the strategic development of various industry technology platforms, contributing to the overall loss [1]. Group 3: Profitability Factors - The reduction in profit was influenced by several factors, including exchange losses, decreased interest income contributions, and increased depreciation and amortization expenses [1]. - The company also recognized certain asset impairment losses, which further impacted the net profit for the year [1].